These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 38761408)

  • 1. Efficacy and safety of bevacizumab in neoadjuvant and concurrent chemoradiotherapy for refractory cervical cancer patients.
    Yang H; Huang SG; Dong M; Wang X; He J; Su H; Liu C; Zhu Y; Wei L; Liu Z
    Biomol Biomed; 2024 Oct; 24(6):1586-1594. PubMed ID: 38761408
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HAEMATOLOGICAL TOXICITIES OF GEMCITABINE PLUS CISPLATIN VERSUS FLUOROURACIL, CISPLATIN, PLUS DOCETAXEL FOLLOWED BY CONCURRENT CHEMORADIOTHERAPY IN LOCOREGIONALLY ADVANCED NASOPHARYNGEAL CARCINOMA.
    Rehman A; Haider G; Ramchand A; Khan SN; Sehar S; Mahmood R; Khattak YR; ; Siddiqa A; Aqeel MA
    J Ayub Med Coll Abbottabad; 2024; 36(1):3-9. PubMed ID: 39585250
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Primary lung tumour stereotactic body radiotherapy followed by concurrent mediastinal chemoradiotherapy and adjuvant immunotherapy for locally advanced non-small-cell lung cancer: a multicentre, single-arm, phase 2 trial.
    Heinzerling JH; Mileham KF; Robinson MM; Symanowski JT; Induru RR; Brouse GM; Corso CD; Prabhu RS; Haggstrom DE; Moeller BJ; Bobo WE; Fasola CE; Thakkar VV; Pal SE; Gregory JM; Norek SL; Begic XJ; Kesarwala AH; Burri SH; Simone CB
    Lancet Oncol; 2024 Nov; ():. PubMed ID: 39615497
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The efficacy and safety of the prophylactic application of PEG-rhG-CSF in radiotherapy with weekly concurrent chemotherapy for cervical cancer.
    Chen H; Ma Y; Wang D; Wu H; Zhang M; Xu Y; Cheng S
    BMC Cancer; 2024 Nov; 24(1):1405. PubMed ID: 39543536
    [TBL] [Abstract][Full Text] [Related]  

  • 5. De-escalated neoadjuvant weekly nab-paclitaxel with trastuzumab and pertuzumab versus docetaxel, carboplatin, trastuzumab, and pertuzumab in patients with HER2-positive early breast cancer (HELEN-006): a multicentre, randomised, phase 3 trial.
    Chen XC; Jiao DC; Qiao JH; Wang CZ; Sun XF; Lu ZD; Li LF; Zhang CJ; Yan M; Wei Y; Chen B; Feng YQ; Deng M; Ma MD; Plichta JK; He YW; Liu ZZ
    Lancet Oncol; 2024 Nov; ():. PubMed ID: 39612919
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Decitabine, venetoclax, and ponatinib for advanced phase chronic myeloid leukaemia and Philadelphia chromosome-positive acute myeloid leukaemia: a single-arm, single-centre phase 2 trial.
    Short NJ; Nguyen D; Jabbour E; Senapati J; Zeng Z; Issa GC; Abbas H; Nasnas C; Qiao W; Huang X; Borthakur G; Chien K; Haddad FG; Pemmaraju N; Karrar OS; Nguyen D; Konopleva M; Kantarjian H; Ravandi F
    Lancet Haematol; 2024 Nov; 11(11):e839-e849. PubMed ID: 39303729
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of Two Modern Survival Prediction Tools, SORG-MLA and METSSS, in Patients With Symptomatic Long-bone Metastases Who Underwent Local Treatment With Surgery Followed by Radiotherapy and With Radiotherapy Alone.
    Lee CC; Chen CW; Yen HK; Lin YP; Lai CY; Wang JL; Groot OQ; Janssen SJ; Schwab JH; Hsu FM; Lin WH
    Clin Orthop Relat Res; 2024 Dec; 482(12):2193-2208. PubMed ID: 39051924
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of prostate radiotherapy in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 × 2 factorial design.
    Bossi A; Foulon S; Maldonado X; Sargos P; MacDermott R; Kelly P; Fléchon A; Tombal B; Supiot S; Berthold D; Ronchin P; Kacso G; Salem N; Calabro F; Berdah JF; Hasbini A; Silva M; Boustani J; Ribault H; Fizazi K;
    Lancet; 2024 Nov; 404(10467):2065-2076. PubMed ID: 39580202
    [TBL] [Abstract][Full Text] [Related]  

  • 9. What Are the Functional, Radiographic, and Survivorship Outcomes of a Modified Cup-cage Technique for Pelvic Discontinuity?
    Mu W; Xu B; Wahafu T; Wang F; Guo W; Zou C; Cao L
    Clin Orthop Relat Res; 2024 Dec; 482(12):2149-2160. PubMed ID: 38991223
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chemotherapy and radiotherapy for advanced pancreatic cancer.
    Haggstrom L; Chan WY; Nagrial A; Chantrill LA; Sim HW; Yip D; Chin V
    Cochrane Database Syst Rev; 2024 Dec; 12(12):CD011044. PubMed ID: 39635901
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial.
    Llovet JM; Kudo M; Merle P; Meyer T; Qin S; Ikeda M; Xu R; Edeline J; Ryoo BY; Ren Z; Masi G; Kwiatkowski M; Lim HY; Kim JH; Breder V; Kumada H; Cheng AL; Galle PR; Kaneko S; Wang A; Mody K; Dutcus C; Dubrovsky L; Siegel AB; Finn RS;
    Lancet Oncol; 2023 Dec; 24(12):1399-1410. PubMed ID: 38039993
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biosimilar monoclonal antibodies for cancer treatment in adults.
    Galvao TF; Livinalli A; Lopes LC; Zimmermann IR; Silva MT
    Cochrane Database Syst Rev; 2024 Nov; 11(11):CD013539. PubMed ID: 39607013
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Abiraterone acetate plus prednisolone with or without enzalutamide for patients with metastatic prostate cancer starting androgen deprivation therapy: final results from two randomised phase 3 trials of the STAMPEDE platform protocol.
    Attard G; Murphy L; Clarke NW; Sachdeva A; Jones C; Hoyle A; Cross W; Jones RJ; Parker CC; Gillessen S; Cook A; Brawley C; Gilson C; Rush H; Abdel-Aty H; Amos CL; Murphy C; Chowdhury S; Malik Z; Russell JM; Parkar N; Pugh C; Diaz-Montana C; Pezaro C; Grant W; Saxby H; Pedley I; O'Sullivan JM; Birtle A; Gale J; Srihari N; Thomas C; Tanguay J; Wagstaff J; Das P; Gray E; Alzouebi M; Parikh O; Robinson A; Montazeri AH; Wylie J; Zarkar A; Cathomas R; Brown MD; Jain Y; Dearnaley DP; Mason MD; Gilbert D; Langley RE; Millman R; Matheson D; Sydes MR; Brown LC; Parmar MKB; James ND;
    Lancet Oncol; 2023 May; 24(5):443-456. PubMed ID: 37142371
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of efficacy and safety of neoadjuvant immunochemotherapy in young and elderly patients with IIA-IIIB non-small-cell lung cancer in real-world practice.
    Liu J; Huang X; Yang Y; Lv W; Wang Y; Xia P; Hu J
    BMC Pulm Med; 2024 Nov; 24(1):592. PubMed ID: 39614293
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety, pharmacokinetics, and pharmacodynamics of LBP-EC01, a CRISPR-Cas3-enhanced bacteriophage cocktail, in uncomplicated urinary tract infections due to Escherichia coli (ELIMINATE): the randomised, open-label, first part of a two-part phase 2 trial.
    Kim P; Sanchez AM; Penke TJR; Tuson HH; Kime JC; McKee RW; Slone WL; Conley NR; McMillan LJ; Prybol CJ; Garofolo PM
    Lancet Infect Dis; 2024 Dec; 24(12):1319-1332. PubMed ID: 39134085
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tamoxifen for adults with hepatocellular carcinoma.
    Naing C; Ni H; Aung HH
    Cochrane Database Syst Rev; 2024 Aug; 8(8):CD014869. PubMed ID: 39132750
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Efficacy and safety of eltrombopag in the treatment of primary immune thrombocytopenia: real-world data from a single medical center].
    Dong XF; Li YL; Li NB; Lin WN; Wang T; Wang HQ; Li LJ; Qu W; Xing LM; Liu H; Wu YH; Wang GJ; Song J; Guan J; Wang XM; Shao ZH; Fu R
    Zhonghua Xue Ye Xue Za Zhi; 2024 Mar; 45(3):271-276. PubMed ID: 38716599
    [No Abstract]   [Full Text] [Related]  

  • 18. Phase II Trial of Cisplatin, Gemcitabine, and Intensity-Modulated Radiation Therapy for Locally Advanced Vulvar Squamous Cell Carcinoma: NRG Oncology/GOG Study 279.
    Horowitz NS; Deng W; Peterson I; Mannel RS; Thompson S; Lokich E; Myers T; Hanjani P; O'Malley DM; Chung KY; Miller DS; Ueland FR; Dizon DS; Miller A; Mayadev JS; Leath CA; Monk BJ
    J Clin Oncol; 2024 Jun; 42(16):1914-1921. PubMed ID: 38574312
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Exploring zinc deficiency using serum Zn levels: consequences and potential solutions in suckling pigs.
    Blavi L; Villagómez-Estrada S; Solà-Oriol D; Pérez JF
    J Anim Sci; 2024 Jan; 102():. PubMed ID: 38035764
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nivolumab plus ipilimumab versus carboplatin-based doublet as first-line treatment for patients with advanced non-small-cell lung cancer aged ≥70 years or with an ECOG performance status of 2 (GFPC 08-2015 ENERGY): a randomised, open-label, phase 3 study.
    Léna H; Greillier L; Cropet C; Bylicki O; Monnet I; Audigier-Valette C; Falchero L; Vergnenègre A; Demontrond P; Geier M; Guisier F; Hominal S; Locher C; Corre R; Chouaid C; Ricordel C;
    Lancet Respir Med; 2024 Oct; ():. PubMed ID: 39486424
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.